UNSPSC 51111873: Tamoxifen

This classification denotes a selective estrogen receptor modulator and protein kinase c inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 094ZI81Y45. European Medicines Agency schedules Tamoxifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10825MIG. Tamoxifen generally arises in the molecular formula C26H29NO.

UNSPSC 51111873 Tamoxifen, a Commodity code, covers the procurement of tamoxifen, a selective estrogen receptor modulator used primarily in breast cancer treatment and prevention. State and local governments acquire tamoxifen through health departments, public health agencies, correctional health systems, and safety-net hospital networks to support inpatient and outpatient oncology services, medication dispensing programs, and institutional formularies. The drug is typically procured as a finished pharmaceutical product in tablet or oral suspension form, often through competitive bidding processes tied to state formulary management, group purchasing agreements, or direct vendor contracts negotiated at the state or regional level.

The source contains no recent state or local contract opportunities tagged to this Commodity code. Without posted RFP, RFQ, IFB, or ITB records, geographic concentration and issuing-body patterns cannot be reliably characterized from current activity. Procurement of brand-name and generic tamoxifen at the state and local level generally flows through established pharmaceutical supply chains, cooperative purchasing vehicles, and state health department contracts rather than open competitive solicitation, which may explain the absence of visible opportunities in public notice databases.